Carmel Valley-Based ADVENTRX Hires Firm to Manage Clinical Study

ADVENTRX Pharmaceuticals, a Carmel Valley-based biopharmaceutical company, announced earlier this month that it hired New Jersey-based Theradex Systems to manage its upcoming phase 3 study of ANX-188 in sickle cell disease.

ADVENTRX's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function which is compromised in a wide range of serious and life-threatening diseases and conditions, it said. 

"The engagement of Theradex is one of the final steps before initiating our phase 3 study of ANX-188 in patients with sickle cell disease experiencing vaso-occlusive crisis," said ANVENTRX CEO Brian M. Culley in an announcement. "We selected Theradex based on its extensive experience in the management and oversight of clinical trials, which includes studies in patients with sickle cell disease and a 29-year collaboration with the National Cancer Institute in the United States."

He added, "We are confident in Theradex's ability to assist us in executing a high-quality, efficient phase 3 study of ANX-188."